An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
暂无分享,去创建一个
S. Iacobelli | P. Chevallier | I. Yakoub-Agha | J. Snowden | A. Elmaagacli | D. Mclornan | S. Schönland | R. Fenk | J. Cornelissen | L. Griškevičius | M. Engelhardt | S. Zeerleder | A. Stoppa | C. Hulin | N. Rabin | E. Meijer | K. Orchard | P. Hayden | J. Mear | N. Schaap | N. Fegueux | L. Koster | J. Mayer | E. Konířová | M. Beksaç | C. Sossa
[1] H. Einsele,et al. ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. , 2022, Transplantation and cellular therapy.
[2] P. Sonneveld,et al. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment , 2022, Frontiers in Oncology.
[3] Shaji K. Kumar,et al. Post-Transplant Maintenance Treatment Options in Multiple Myeloma , 2021, Oncology and Therapy.
[4] H. Goldschmidt,et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] P. Hari,et al. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma , 2020, British journal of haematology.
[6] G. Morgan,et al. Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma , 2020, British journal of haematology.
[7] M. Dimopoulos,et al. Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. , 2020, Clinical lymphoma, myeloma & leukemia.
[8] M. Mohty,et al. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk , 2019, Haematologica.
[9] W. Wiktor-Jedrzejczak,et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party , 2017, Haematologica.
[10] D. Dingli,et al. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] J. Crowley,et al. Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma , 2016, Blood Cancer Journal.
[12] E. Steyerberg,et al. [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.
[13] D. Dingli,et al. Impact of early relapse after auto-SCT for multiple myeloma , 2008, Bone Marrow Transplantation.